Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

ConserV Bioscience Pan-coronavirus Project Awarded UK Aid Funding by the UK Vaccine Network, Delivered by Innovate UK

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded UK Aid funding to advance the development of its pan-coronavirus vaccine candidate, UNICOR-v.

The project was selected by the UK Vaccine Network (UKVN) for the award under the competition “Vaccines for epidemic diseases: Readiness for clinical development and regulatory submission.” This is one of the twenty-two projects funded by the Department of Health and Social Care as part of the UKVN, a UK Aid program to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs).

ConserV specializes in identifying broadly protective antigens for highly mutable viruses. The grant will fund the preclinical development of an intra-dermal formulation of UNICOR-v, which consists of twelve antigens from conserved regions of internal viral proteins that include clusters of reactive T-cell epitopes for multiple human leukocyte antigens (HLAs).

The project will compare four different formulations of UNICOR-v, delivering antigens as synthetic peptides or encoded in mRNA. Preclinical immunogenicity and efficacy of the candidate vaccines will be evaluated, providing the necessary evidence to enter clinical trials.

UNICOR-v aims to protect against all coronaviruses including those from alpha, beta, delta, and gamma genera. The betacoronavirus genus includes SARS-Cov-1, responsible for the SARS outbreak in 2003, MERS, responsible for the outbreak in 2012-13, and SARS-Cov-2, responsible for the Covid-19 pandemic, all of which originated from viruses jumping from animal hosts to humans. Alphacoronaviruses include strains responsible for the common cold in humans amongst other viruses that infect other mammals.

Gammacoronaviruses are mainly found in birds, whereas delta coronavirus infects mammals and birds. UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2, avoiding the need for frequent booster vaccinations in response to variants that escape vaccine-induced antibody responses.

Scientists predict that the frequency and severity of epidemics are increasing, driven by human activities and their impact on the environment. Designing a vaccine as an emergency response to an emergent virus takes time during which millions of lives are at risk and considerable economic damage can be done, as demonstrated in the Covid-19 pandemic. pre-pandemic vaccines are necessary to protect against viruses that have not yet emerged in humans.

Kimbell Duncan, Chief Executive Officer of ConserV Bioscience, commented: “Our mission is to develop safe and effective vaccines which offer broad protection against infections from viruses that mutate frequently. We are grateful to the UKVN and Innovate UK for being selected for this award which will help us advance UNICOR-v into clinical trials.”

Dr. Olga Pleguezuelos, Chief Science Officer of ConserV, commented: “We are very excited to advance the development of UNICOR-v with UKVN and Innovate UK’s support. ConserV Bioscience is committed to creating a vaccine that provides readiness against future coronaviruses.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine